Allergy Therapeutics starts field study in advance of pivotal Phase III Grass trial

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the screening of the first patient in its exploratory field study (G309) to evaluate the efficacy and safety of Grass MATA MPL in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposure. Grass MATA MPL is a short course, aluminium-free allergen-specific immunotherapy that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.

This double-blind, placebo controlled, randomised study will run for one year and involve approximately 150 patients over 12 sites across Germany and the USA. The primary objective of this exploratory field study is to evaluate the safety and efficacy of its optimized Phase III dose of 27,600 SU Grass MATA MPL on grass pollen-induced rhinoconjunctivitis. The primary endpoint is the combined symptom medication score (CSMS) averaged over the peak grass pollen season. Results from the study will provide valuable information in preparation of the pivotal Phase III study (G306).

The breakthrough study design brings state of the art learnings in field trial methodology to the allergy immunotherapy research field. It is not only designed to evaluate safety and efficacy but is the first subcutaneous immunotherapy (SCIT) study to evaluate different placebo options, including normal saline. Moreover, the study combines several Phase II and Phase III endpoints to support the validation of the regulatory mandated primary endpoint and includes extensive biomarker analysis. These data aim to drive forward and underpin success in subsequent phase III trials for the Group’s whole MATA MPL programme including grass, birch and ragweed.

The Group, which has mitigation strategies in place to ensure the Grass MATA MPL clinical development programme continues despite the COVID-19 situation, expects results from the field study in H2 2021.

Manuel Llobet, CEO at Allergy Therapeutics, stated: “This exploratory grass trial will drive study design innovation in the allergy field and is an important intermediate step for the optimisation of our upcoming pivotal Phase III grass field trial, which will maximise the chances of success and entry into the US market. Parts of this protocol are ground-breaking and have the potential to significantly enhance science in this area.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Allergy therapeutics plc

More articles like this

What are allergies?

Warmer weather is upon us here in the Northern Hemisphere. While it’s a welcome reward for surviving the winter to peel a few layers of clothing off, springtime is also when those unwelcome spring allergies start to blossom.

Why allergy season is longer and stronger this year

Allergy season is getting longer and there’s more pollen in the air. That’s bad news for people with seasonal allergies, and the situation is unlikely to improve until the climate stops warming, experts say. A recent study found that pollen

Infant allergies impacted by their mode of birth

Researchers have found a causal link between caesarean section birth, low intestinal microbiota and peanut sensitivity in infants, and they report the effect is more pronounced in children of Asian descent than others, in a recently published paper

Allergy Therapeutics appoints BDO as new Group auditors

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapy, has announced, that following a competitive tender process, BDO LLP has been appointed as its external auditor for the year ended 30 June 2021. The

Worsening spring allergies linked to climate change

If you’ve noticed your allergies getting worse every spring, you are not alone, allergy experts say.  The spring allergy season — which takes place from February to May each year and impacts roughly 24 million Americans — is likely intensifying as a result

Allergies surge after a year mostly indoors

A year into the pandemic, allergy season is back, and worse than before. Doctors told CBS2 that their waiting rooms are full of people sniffling and coughing, terrified they have the coronavirus. To make matters worse for worried

How much peanut is needed to trigger allergies?

An estimated 6 million Americans may suffer from peanut allergies. Tiny amounts of peanut protein can lead to hives, itching, tingling in the mouth, shortness of breath or nausea within minutes. For individuals with severe peanut allergies, food-induced

COVID-19 or allergies? What you need to know this spring

It’s the season of sniffling and sneezing, but this year as Manitobans continue to deal with COVID-19, allergy symptoms can leave many wondering if they should be more concerned. More people are spending family time outdoors while social distancing,